ISSN: 2078-6891
Journal Home
Journal Guideline
Journal of Gastrointestinal Oncology Q3 Unclaimed
Journal of Gastrointestinal Oncology is a journal indexed in SJR in Oncology and Gastroenterology with an H index of 55. It has an SJR impact factor of 0,6 and it has a best quartile of Q3. It has an SJR impact factor of 0,6.
Type: Journal
Type of Copyright:
Languages:
Open Access Policy:
Type of publications:
Publication frecuency: -
- €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
0,6
SJR Impact factor55
H Index236
Total Docs (Last Year)758
Total Docs (3 years)8198
Total Refs1571
Total Cites (3 years)721
Citable Docs (3 years)1.95
Cites/Doc (2 years)34.74
Ref/DocOther journals with similar parameters
Cancer Management and Research Q3
Journal of Breast Cancer Q3
Breast Cancer: Basic and Clinical Research Q3
Oncology Letters Q3
Clinical Medicine Insights: Oncology Q3
Compare this journals
Aims and Scope
Best articles by citations
Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer
View moreAn unusual case of obstructive jaundice: ampullary Burkitt lymphoma
View moreChanging paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation
View moreAn unusual case of primary acinar cell carcinoma of the liver and its treatment
View morePreferential use of imaging modalities in staging newly diagnosed rectal cancer: a survey of US radiation oncologists
View moreCT-based assessment of visceral adiposity and outcomes for esophageal adenocarcinoma
View moreClinical outcomes of endoscopic submucosal tunnel dissection compared with conventional endoscopic submucosal dissection for superficial esophageal cancer: a systematic review and meta-analysis
View moreMaximizing response: a case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma
View moreAggressive mutation in a familial adenomatous polyposis syndrome family: when phenotype guides clinical surveillance
View moreFirst line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age
View moreShort course radiation therapy for rectal cancer in the elderly: can radical surgery be avoided?
View moreStaging and survival of colorectal cancer (CRC) in octogenarians: Nationwide Study of US Veterans
View moreAdvances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference
View moreEpidemiological profile of gastric cancer in the northwestern region of Algeria: about 116 cases
View moreOsteonecrosis of the jaw associated with ziv-aflibercept
View moreCost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer
View moreMolecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets
View moreTrends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005-2014
View moreOutcomes of endoscopic submucosal dissection in esophageal adenocarcinoma staged T1bN0 by endoscopic ultrasound in non-surgical patients
View moreInvestigation of the changes in the expression levels of MOZ gene in colorectal cancer tissues
View moreGemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer - retrospective analysis of response
View moreThe platelets-neutrophils to lymphocytes ratio: a new prognostic marker in metastatic colorectal cancer
View moreQuality of life as a fundamental outcome after curative intent gastrectomy for adenocarcinoma: lessons learned from patients
View moreClinical fate of T0N1 esophageal cancer: results from the National Cancer Database
View more
Comments